贝伐珠单抗治疗新诊断胶质母细胞瘤的神经认知、症状与健康相关生活质量结局:NRG/RTOG 0825随机试验
NRG Oncology RTOG 0825试验的补充分析,在508例随机患者中评估贝伐珠单抗联合标准放化疗对新诊断胶质母细胞瘤患者神经认知功能、症状和生活质量的影响。结果显示贝伐珠单抗组在后期时间点(第22、34、46周)神经认知功能、症状和生活质量恶化更明显,且基线和早期变化可预测生存结局。
要点
- 贝伐珠单抗组在第22、34、46周神经认知测试和患者报告结局恶化更明显
- 基线和早期神经认知功能及患者报告结局变化可预测总生存和无进展生存
- 两组至恶化时间无显著差异
核心结论
- 在NRG/RTOG 0825 III期试验中,贝伐珠单抗治疗患者随时间出现更明显的神经认知功能、症状和生活质量恶化。
- 基线和早期神经认知功能及患者报告结局变化对生存终点具有预后价值。
研究设计与样本
- NRG Oncology RTOG 0825 III期随机试验的补充分析,共508例随机患者参与。
- 在基线和纵向对无进展患者亚组完成神经认知测试、MDASI-BT和EORTC QLQ-C30/BN20评估。
主要发现
- 基线和早期神经认知功能及患者报告结局变化对总生存和无进展生存具有预后价值。
- 两组至恶化时间无差异。
- 第6周时贝伐珠单抗组在执行功能神经认知测试和MDASI-BT认知功能量表上改善更明显,但EORTC认知功能量表报告下降更明显。
- 第22、34、46周时贝伐珠单抗组在神经认知测试及认知、沟通、社会功能、运动症状、一般症状和干扰等患者报告结局指标上恶化更明显。
临床怎么用
- 在胶质母细胞瘤治疗决策中应关注贝伐珠单抗对神经认知功能、症状和生活质量的长期影响。
- 基线和早期神经认知功能及患者报告结局变化可用于预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient-reported outcomes (PRO) over time in bevacizumab-treated patients. The present report provides additional results of patient-centered outcomes over time and their prognostic association with survival endpoints. METHODS: NCF tests, MD Anderson Symptom Inventory - Brain Tumor Module (MDASI-BT), and European Organization for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire with brain cancer module (QLQ-C30/BN20) were completed in a subset of progression-free patients at baseline and longitudinally. The prognostic value of baseline and early changes in NCF and PROs and differences between treatments from baseline to follow-up assessments were evaluated. RESULTS: A total of 508 randomized patients participated. Baseline/early changes in NCF and PROs were prognostic for OS and PFS. No between-arm differences in time to deterioration were found. At week 6, patients treated with bevacizumab evidenced greater improvement on NCF tests of executive function and the MDASI-BT Cognitive Function scale, but simultaneously reported greater decline on the EORTC Cognitive Function Scale. At later time points (weeks 22, 34, and 46), patients treated with bevacizumab had greater worsening on NCF tests as well as PRO measures of cognitive, communication, social function, motor symptoms, general symptoms, and interference. CONCLUSION: The collection of patient-centered clinical outcome assessments in this phase III trial revealed greater deterioration in NCF, symptoms, and QOL in patients treated with bevacizumab. Baseline and early change in NCF and PROs were prognostic for survival endpoints.
引用
- Wefel JS, Armstrong TS, Pugh SL, et al. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro Oncol. 2021. PMID: 33515019. doi:10.1093/neuonc/noab011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。